Higher risk of cardiovascular mortality linked with timolol

Article

Cardiovascular mortality tends to increase in black persons with diagnosed and treated open-angle glaucoma (OAG) and ocular hypertension (OH), and the risk of death and cardiovascular mortality are increased further in those patients treated with timolol, according to a paper published in the March 11, 2008 issue of the Archives of Ophthalmology.

Cardiovascular mortality tends to increase in black persons with diagnosed and treated open-angle glaucoma (OAG) and ocular hypertension (OH), and the risk of death and cardiovascular mortality are increased further in those patients treated with timolol, according to a paper published in the March 11, 2008 issue of the Archives of Ophthalmology.

Suh-Yuh Wu of Stony Brook University, NY (US) and colleagues conducted the Barbados Eye Study in 4092 participants, who were predominantly black and were aged 40-84 years at baseline. At baseline, 300 participants had glaucoma, of whom 141 had been diagnosed and treated.

After nine years, 764 (19%) participants were deceased. Mortality was unrelated to overall OAG at baseline after adjustment for confounders. However, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG (relative risk [RR], 1.38, p=0.07) and was significantly higher with treatment involving timolol maleate (RR, 1.91, p=0.04). Cardiovascular deaths also tended to increase in persons with OH at baseline (n=498; RR, 1.28, p=0.06).

The results led the study authors to conclude that cardiovascular mortality within this population tended to increase in persons with previously diagnosed/treated OAG and OH. The excess mortality was particularly significant in patients treated with timolol (60%) either alone or in combination, and thus warrants further investigation.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.